Marion Merrell Dow
Executive Summary
Licenses North American rights to Toray's oral prostacyclin TRK-100, a compound with potential cardiovascular applications. Marion Merrell Dow will be responsible for development of the product for the U.S. and Canadian markets, while Toray will supply the bulk active ingredient.